Scarica l'app Stockscreener
14.52
0.28%
0.04
Dopo l'orario di chiusura:
14.54
0.02
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Keros Therapeutics Inc. Building a Base Near SupportJuly 2025 Technicals & Trade Opportunity Analysis - newsyoung.net
How to build a dashboard for Keros Therapeutics Inc. stockTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Connor Clark & Lunn Investment Management Ltd. Has $1.31 Million Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Applying Elliott Wave Theory to Keros Therapeutics Inc.Dip Buying & High Accuracy Swing Entry Alerts - Newser
Applying sector rotation models to Keros Therapeutics Inc.Market Trend Review & High Conviction Buy Zone Alerts - Newser
Why Keros Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Volume & Growth Focused Stock Reports - Newser
Is Keros Therapeutics Inc. forming a breakout pattern2025 Risk Factors & Consistent Income Trade Recommendations - thegnnews.com
Is Keros Therapeutics Inc. showing signs of accumulation2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Using data tools to time your Keros Therapeutics Inc. exitMarket Growth Review & Low Risk High Reward Ideas - Newser
What makes Keros Therapeutics Inc. stock price move sharply2025 Key Lessons & Weekly High Return Stock Opportunities - thegnnews.com
Does Keros Therapeutics Inc. qualify in momentum factor screeningDay Trade & Community Consensus Stock Picks - Newser
Tejara Capital Ltd Purchases New Shares in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. continue its uptrend2025 Stock Rankings & Safe Entry Trade Reports - Newser
Is this a good reentry point in Keros Therapeutics Inc.Quarterly Trade Report & Weekly Momentum Picks - Newser
Key metrics from Keros Therapeutics Inc.’s quarterly dataPortfolio Return Report & Technical Entry and Exit Tips - Newser
Signal strength of Keros Therapeutics Inc. stock in tech scannersEarnings Recap Report & Daily Profit Maximizing Tips - Newser
Applying chart zones and confluence areas to Keros Therapeutics Inc.Entry Point & Community Trade Idea Sharing Platform - Newser
Combining price and volume data for Keros Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Is Keros Therapeutics Inc. stock trending bullish2025 Winners & Losers & Target Return Focused Picks - thegnnews.com
Can Keros Therapeutics Inc. hit a new high this monthForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Exit strategy if you’re trapped in Keros Therapeutics Inc.2025 Trading Recap & Growth Focused Entry Reports - Newser
Statistical indicators supporting Keros Therapeutics Inc.’s strengthQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
Keros Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Levels & Safe Entry Point Alerts - sundaytimes.kr
Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings - MarketBeat
Q3 EPS Estimate for Keros Therapeutics Lowered by Analyst - MarketBeat
Technical Bounce Expected in Keros Therapeutics Inc. Next Week2025 Year in Review & Community Consensus Picks - thegnnews.com
Keros Therapeutics Reports Strong Revenue Growth - TipRanks
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - Defense World
William Blair Predicts Lower Earnings for Keros Therapeutics - Defense World
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com Canada
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Keros Therapeutics Announces Strategic Realignment and Leadership Changes - TipRanks
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Keros discontinues cibotercept development, announces leadership changes By Investing.com - Investing.com South Africa
Keros discontinues cibotercept development, announces leadership changes - Investing.com
Keros Therapeutics Announces Discontinuation of Cibotercept Development and Leadership Changes for Strategic Realignment - Quiver Quantitative
Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan
Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):